OX40 Antibody Epitope Binding Specificity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for targeting OX40 in cancer and autoimmune diseases lack effective antibodies that specifically bind to the OX40 protein, particularly at the epitope spanning amino acids 266-277, which is crucial for enhancing immune responses.
Innovation Solution
Development of antibodies, antigen-binding fragments, or recombinant proteins that specifically bind to the epitope comprising amino acids 266-277 of the human OX40 polypeptide, with defined hypervariable regions and framework regions, capable of recognizing the OX40 protein with high affinity, including monoclonal antibodies and immunoconjugates for therapeutic and diagnostic applications.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If current methods for targeting OX40 are used, then general immune response modulation may be achieved, but specific binding to the OX40 epitope (amino acids 266-277) is insufficient
Solution Approach 1:
The antibody is designed to bind specifically to a localized epitope region (amino acids 266-277) of the OX40 protein rather than interacting with multiple sites. This localized binding approach enhances both specificity and functional reliability by concentrating the immune modulatory effect at the precise epitope location, resolving the contradiction between binding precision and immune response effectiveness.
2Reliability
If antibodies with high binding affinity to OX40 are developed, then therapeutic efficacy is improved, but complexity of antibody structure increases
Solution Approach 1:
The invention extracts and focuses on the essential functional components required for OX40 binding by defining specific hypervariable region sequences that are critical for high-affinity epitope recognition. By identifying and utilizing only the necessary amino acid sequences in the HVRs, the antibody achieves high therapeutic efficacy without unnecessary structural complexity, maintaining simplicity while ensuring effectiveness.
3Measurement precision
If monoclonal antibodies with defined HVR sequences are produced, then binding precision to OX40 epitope is enhanced, but manufacturing complexity increases
Solution Approach 1:
The invention specifies precise amino acid sequences for the hypervariable regions (HVR-H1, HVR-H2, HVR-H3, HVR-L1, HVR-L2, HVR-L3) that determine epitope binding precision. By defining these critical parameters (amino acid sequences) while allowing flexibility in framework regions and constant domains, the patent achieves high epitope recognition accuracy while facilitating standardized manufacturing processes through clear sequence specifications.
Data Source
AI summary
The invention provides antibodies immunoreactive with human OX40 and methods of using the same. The antibodies are reactive with a portion of the C-terminus of the human OX40 protein that includes amino acids 266-277. The antibodies are useful for detecting OX40 protein expression in human tissue samples, including by immunohistochemistry, immunofluorescence, or immunoblot.